 |
|
|||||||||||||||
|
||||||||||||||||
| News in Brief - January 2010 Brief items of the latest industry news... |
| Appointments - January 2010 Stay up to date with the latest changes in personnel... |
| Biomet Announces Increased Support in 2010 to OREF Orthopaedic Graduate Medical Education Partnership Biomet, Inc. and the OREF have announced that Biomet, Inc. is continuing... |
| Sandvik Extends Range of Medical Grade Titanium to Include?New Forms Sandvik has extended the range of forms in which it provides medical grade... |
| BioCeramic Therapeutics Appoints New CEO BioCeramic Therapeutics Limited have recently announced the appointment of... |
| Biocomposites launches geneX®ds Biocomposites have launched geneX®ds, a dual syringe... |
| One More Step Forward for Biovision Medical Limited Since the introduction of the Human Tissue Regulations 2007... |
|
Company News In Brief
 Össur recently announced that Lou Ruggiero will be joining the Össur Americas organization as the new Vice-President of Sales and Business Development.
Mr. Ruggiero comes to Össur with a background of leadership and achievements. He was Chief Sales and Marketing Officer at DJO from 2003-2007, where he doubled sales growth to $375 million. Most recently, he held the position of Chief Commercial Officer of Stereotaxis, where he was responsible for worldwide Commercial Operations, increasing revenue by 36%. Mr. Ruggiero received his MBA from the Kellogg Graduate School of Management at Northwestern University.
“We are very excited about bringing someone of Lou’s proven experience onboard at Össur,” stated Mahesh Mansukhani, President of Össur Americas. “Lou brings to Össur a strong track record of driving sales growth, as well as world-class orthopaedic experience that will enable us to successfully achieve our aggressive growth goals.” Lou Ruggiero commented, “I am looking forward to joining the Össur team. With our broad product line, commitment to innovative technology and strong leadership, I am extremely confident that we are well positioned for success.”Smith & Nephew Orthopaedics is providing over $2 million in implants and surgical instruments for use by orthopaedic surgeons in the treatment of survivors of the devastating earthquake that hit Haiti in January.
Hope Force International will distribute the products that will be used by orthopaedic surgeons operating out of King’s Hospital in Port-au-Prince.
Joseph DeVivo, president of Smith & Nephew Orthopaedics, said the company had the means to help and wants to do everything it can to connect its technology to people and organisations who need it the most.Global Orthopaedics (UK) Ltd have announced the opening of their new production facility in Portsmouth. Since opening in 2002 they have seen increased sales and growth and have now out grown their original premises.
The new site of over 10,000 square feet will allow them to expand their production. Plus, additional office space will also allow the following:
Biomet Announces Increased Support in 2010 to OREF Orthopaedic Graduate Medical Education Partnership Biomet, Inc. and the Orthopaedic Research and Education Foundation (OREF) have announced that Biomet, Inc. is continuing its multi-year commitment for the funding of graduate medical education programs in orthopaedic surgery. Biomet will increase its funding in 2010, with a donation of $1.4 million for the purposes of funding orthopaedic fellowship and resident enhancement programs. Fellowship funding will underwrite advanced education in the sub-specialties of adult reconstruction, upper extremity, sports medicine, oncology, trauma, and spine. Resident Enhancement funding will provide support for orthopaedic residency education, resident travel to professional meetings, visiting professors, books, and other educational initiatives. Included in Biomet’s donation for 2010, is funding specifically designated to support the 2010 OREF Resident Research Symposia. OREF will continue to have full responsibility for receiving, reviewing and approving grant requests. OREF will award grants at its sole discretion, based on the merits of the request and the needs of the requesting teaching institution. Grant applications will be reviewed by the OREF Educational Grants Board, an independent panel of physicians who have no industry conflicts. “In 2009 Biomet made the first donation of a multi-year commitment to support graduate medical education. In 2010 we are expanding that commitment. Through our partnership with the OREF we have established an ethical, transparent and independent method to provide needed funding for deserving resident and fellowship programs,” said Jeffrey R. Binder, Biomet President and Chief Executive Officer. “In 2009 we were pleased to have participated in funding 31 of the 50 fellowship grants that were awarded by the OREF. Additionally, Biomet participated in funding 39 resident enhancement grants. Our continuing partnership with OREF and our increased financial commitment will directly contribute to education of the next generation of orthopaedic surgeons.” Sandvik Extends Range of Medical Grade Titanium to Include?New Forms Sandvik has extended the range of forms in which it provides medical grade titanium, introducing flat product forms. The offering now includes titanium wire and round bar in dimensions between 6mm and 70mm in diameter as well as flat forms in a wide range of dimen-sions. As a consequence, medical device OEMs and other manufacturers can now access a complete and integrated high quality metallurgical solution from one source, encompassing medical grade stainless steel, titanium and cobalt chrome.
The quality of the product, all of which is melted within Europe, is assured by Sandvik’s testing procedures and then managed via its quality control and distribution system. This ensures the full traceability of the product throughout the supply chain.
Stephen Cowen, General Manager at Sandvik Bioline, explains:
“By continually extending our range of titanium products we are able to provide a comprehensive supply chain solution to our customers. Whether they purchase stock annually or adopt a just-in-time approach and spot buy, we have the fully integrated quality assured solution they require.
“Medical device companies operate in a highly competitive market and are continually looking for efficiency improvements without compromising on quality or service delivery.
“As a consequence they are seeking a small number of strategic partners rather than a larger number of suppliers. By extending our metallurgical solutions and combining them with our cutting edge production expertise we are the ideal partner for medical device companies.”
BioCeramic Therapeutics Appoints New CEO BioCeramic Therapeutics Limited have recently announced the appointment of Ian Brown as CEO. This was part of a succession plan that was developed by the board of directors over the past six months for its chief executive officer position, which will see Daniel Green, BioCeramic Therapeutics outgoing founding CEO, remain as a Director on the Board of the company.  Prior to joining BioCeramic Therapeutics, Ian held senior executive positions with Chromogenix (previously Kabi Pharmacia) in Sweden, Instrumentation Laboratory in Italy, Cordlife, SDP Technology and Avanti Capital. Ian has served as a non executive director on a number of boards and as Chair and deputy Chair. In addition to his significant international corporate and business experience, Ian has led teams in M&A transactions and post deal integration. His experience also covers start-ups, divestments and spin-outs, as well as private and public company capital raisings and IPO’s.
Ian is a member of the Course Advisory Committee for the Masters of Entrepreneurship and Innovation Degree at the Australian Graduate School of Entrepreneurship (AGSE). Ian has an MBA and is a Fellow of both the Australian Institute of Company Directors and Australian Institute of Management, and is an alumnus of both INSEAD in France and MBS in Australia.
“This is an incredibly exciting and dynamic time for BioCeramic Therapeutics,” said Brown. “I am honoured to have the opportunity to continue BioCeramic Therapeutics’ strong leadership and commitment to serving our shareholders and employees. BCT stood out from the crowd with its broad pipeline and nearness to the market with a range of development programmes including bioceramics for hard tissue treatment and flexible biomimetic scaffold for tissue engineering.”
Dr Stephan Rietiker, chairman of the board of directors, said, “We are excited to have Ian join BCT at this time. The company is in its strongest ever position and is now focused on commercial deals, licensing, marketing and product sales.”
Biocomposites launches geneX®ds Biocomposites have launched geneX®ds, a dual syringe mixing and minimally invasive delivery system containing geneX, the unique resorbable bone graft material with a negative surface charge. The powder and liquid components of geneX are provided pre-packed in separate syringes. The syringes connect together and allow a faster, simpler and cleaner way for mixing geneX. The resulting setting paste can then be delivered through an 8cm dispenser. ggeneX®ds is ideal for difficult-to-reach surgical sites or minimally invasive procedures. Biocomposites’ Managing Director Stephen Bratt explained, “Expanding clinical evidence supporting the efficacy of ZPC technology in trauma has prompted surgeons’ requests for a geneX delivery system for complex cases. geneX®ds addresses the surgeons’ needs for an easy-to-use mixing and delivery kit that will present geneX to a much wider surgeon and patient base. One More Step Forward for Biovision Medical Limited Since the introduction of the Human Tissue (Quality and Safety for Human Application) Regulations 2007, Biovision Medical Limited have been working towards achieving full compliance with the new legislation. That goal has now been achieved with the granting of a licence for the company to store, distribute, import and export tissue intended for human application. This licence is very important to the continued development of the company as it will provide a solid platform from which to expand its operations in this field, encouraging further technical development and providing future employment opportunities at the company’s headquarters in the United Kingdom and at its facilities across the globe. Stay up to date with the latest changes in personnel Zimmer Holdings, Inc. recently announced that Jeffrey B. Paulsen has joined the Company as Group President, Global Businesses. He will have responsibility for Zimmer Spine, Zimmer Dental, Zimmer Trauma and Zimmer Orthopaedic Surgical Products. Mr. Paulsen will report to David Dvorak, Zimmer Holdings President and Chief Executive Officer.
“We are delighted that Jeff is joining Zimmer to help us drive innovation and growth in our Global Businesses Group,” said Mr. Dvorak. “The markets that these businesses serve are expanding at attractive rates, and we have placed a strategic priority on accelerating our growth in these areas. Jeff has an outstanding record of executive leadership in medical devices, as well as in other industries, and we look forward to his contributions.”
Mr. Paulsen most recently served as Chief Operating Officer for MPS Group Inc., a privately held environmental services and facility management firm.
|
top of page
readers comments
contact us
webmaster
legal notices
home
subscribe
Copyright 2010 © Pelican Magazines Ltd -
developed by webfront ltd
| Current Issue | Orthopaedic Products | Coffe Break | Future Events | Articles | Company Info | OPNews |